Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain.

Cawston H, Davie A, Paget MA, Skljarevski V, Happich M.

Eur Spine J. 2013 Sep;22(9):1996-2009. doi: 10.1007/s00586-013-2804-7. Epub 2013 May 18. Review.

2.

Drug therapy for the treatment of chronic nonspecific low back pain: systematic review and meta-analysis.

Chung JW, Zeng Y, Wong TK.

Pain Physician. 2013 Nov-Dec;16(6):E685-704. Review.

3.

A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.

Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P.

Pain Pract. 2013 Mar;13(3):239-52. doi: 10.1111/j.1533-2500.2012.00578.x. Epub 2012 Jun 21. Review.

PMID:
22716295
4.

The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.

Myers J, Wielage RC, Han B, Price K, Gahn J, Paget MA, Happich M.

BMC Musculoskelet Disord. 2014 Mar 11;15:76. doi: 10.1186/1471-2474-15-76. Review.

5.

Efficacy and safety of duloxetine in patients with chronic low back pain.

Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M.

Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85. doi: 10.1097/BRS.0b013e3181d3cef6.

PMID:
20461028
6.

Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons.

Ney JP, Devine EB, Watanabe JH, Sullivan SD.

Pain Med. 2013 May;14(5):706-19. doi: 10.1111/pme.12091. Epub 2013 Apr 22.

7.

Pharmacologic management of chronic low back pain: synthesis of the evidence.

White AP, Arnold PM, Norvell DC, Ecker E, Fehlings MG.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S131-43. doi: 10.1097/BRS.0b013e31822f178f. Review.

PMID:
21952185
8.

Duloxetine for treating painful neuropathy or chronic pain.

Lunn MP, Hughes RA, Wiffen PJ.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007115. doi: 10.1002/14651858.CD007115.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD007115.

PMID:
19821395
9.

Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial.

Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, Patrick K.

J Pain. 2010 Dec;11(12):1282-90. doi: 10.1016/j.jpain.2010.03.002. Epub 2010 May 15.

PMID:
20472510
10.

Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial.

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM.

Curr Med Res Opin. 2011 Dec;27(12):2361-72. doi: 10.1185/03007995.2011.633502. Epub 2011 Nov 9. Erratum in: Curr Med Res Opin. 2012 May;28(5):822.

PMID:
22017192
11.

Duloxetine use in chronic low back pain: treatment patterns and costs.

Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Pharmacoeconomics. 2012 Jul 1;30(7):595-609. doi: 10.2165/11598130-000000000-00000.

PMID:
22686662
12.

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Jun;11(3):219-36. doi: 10.1007/s40258-013-0031-3.

PMID:
23616247
13.

A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

Citrome L, Weiss-Citrome A.

Postgrad Med. 2012 Jan;124(1):83-93. doi: 10.3810/pgm.2012.01.2521. Review.

PMID:
22314118
14.

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.

Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B.

BMC Neurol. 2009 Feb 10;9:6. doi: 10.1186/1471-2377-9-6.

15.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
16.

Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions.

Gaynor PJ, Liu P, Weller MA, Wohlreich MM.

Curr Med Res Opin. 2013 May;29(5):549-60. doi: 10.1185/03007995.2013.784191. Epub 2013 Apr 3.

PMID:
23477538
17.

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M.

Value Health. 2013 Mar-Apr;16(2):334-44. doi: 10.1016/j.jval.2012.12.006.

18.

Antidepressants in the treatment for chronic low back pain: questioning the validity of meta-analyses.

Williamson OD, Sagman D, Bruins RH, Boulay LJ, Schacht A.

Pain Pract. 2014 Feb;14(2):E33-41. doi: 10.1111/papr.12119. Epub 2013 Oct 17. Review.

PMID:
24460577
19.

Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study.

Chen S, Wu N, Boulanger L, Fraser K, Zhao Z, Zhao Y.

J Med Econ. 2011;14(4):411-20. doi: 10.3111/13696998.2011.585676. Epub 2011 May 26.

PMID:
21615268
20.

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Wielage R, Bansal M, Wilson K, Klein R, Happich M.

Spine (Phila Pa 1976). 2013 May 15;38(11):936-46. doi: 10.1097/BRS.0b013e31828264f9.

PMID:
23250234
Items per page

Supplemental Content

Write to the Help Desk